Warnex Inc.

Warnex Inc.

November 08, 2005 08:30 ET

Warnex third quarter results conference call notice

LAVAL, QC, Nov. 8 - Warnex Inc. (TSX:WNX), will host a Conference
Call to discuss its third quarter results on Monday, November 14, 2005, at
10:00am EST. Warnex invites all interested parties to participate. Third
quarter results will be released on Friday, November 11, 2005, after market
close.



Warnex would like to invite all to participate by dialling 416-640-4127
or 1-800-814-3911. You will be put on hold until the conference call
begins.

On the call from Warnex will be:

Mark Busgang President & CEO
Denis Pellerin Chief Financial Officer

A question and answer session will follow, at which time the operator
will direct participants as to the correct procedure for submitting
questions.

A live audio webcast of the conference call will be available at
www.warnex.ca.

A telephone replay of the conference call will also be available on
November 14, 2005, through November 21, 2005. To access the replay,
dial 416-640-1917 or 1-877-289-8525 and enter reservation number
21158804.


About Warnex

Warnex (www.warnex.ca) is a publicly traded (TSX: WNX) Canadian
biotechnology company devoted to protecting public health by providing
advanced diagnostic and quality control products and services to the
pharmaceutical, agri-food, and healthcare sectors. Warnex's genomics-based
technology offers a versatile detection platform that produces accurate
results rapidly, using Real-Time PCR technology combined with unique genetic
markers and software. Applications range from pathogen detection in foods and
GMO testing to farm-to-fork traceability using Molecular Bar Codes. Our
development pipeline includes applications in the detection of viruses,
allergens, toxins, yeasts, and fungi, as well as meat speciation and
bioterrorism. Warnex's profitable and growing analytical, bioanalytical, and
clinical service groups offer a variety of quality control services, method
development and validation, contract R&D, bioavailability and bioequivalence
studies for clinical trials, and medical laboratory testing.

Contact Information